Meta AnalysisID 2829
异丙肌苷在非HIV和非癌症临床状况中的疗效
CRD42016033054
What is the efficacy of inosine pranobex in non-HIV and non-tumor clinical applications?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2829
- Evidence Id
- 11387
- Core Evidence Id
- 11387
- Source Meta Analysis Id
- 2772
- Herb2 Meta Analysis Id
- HBMA002772
- Crd Id
- CRD42016033054
- Title
- The efficacy of inosine pranobex in non-HIV and non-cancer clinical conditions
- Review Question
- What is the efficacy of inosine pranobex in non-HIV and non-tumor clinical applications?
- Study Type Included
- Preferably randomized clinical trials with application of Inosine pranobex in different diseases. Data should be analyzable, and published in English.
- Condition Being Studied
- Literature data concerning studies related to clinical applications of Inosine pranobex in patients with the non-HIV and non-tumor diseases, including human papillomavirus (HPV, genital warts), herpes simplex virus (HSV), influenza, zoster, respiratory tract viral infections, recurrent infections, measles, hepatitis, chronic fatigue, poststroke infection, subacute sclerosing panencephalitis (SSPE), amyotrophic lateral sclerosis, multiple sclerosis, alopecia areata/totalis, hearing loss will be comprehensively analyzed.
- Participant
- Inclusion: Patients with corresponding diseases in point 18. Exclusion: HIV or cancer patients, pregnancy. Other criteria are listed in each different study.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion criteria: 1) randomized controlled trial concerning the clinical application of inosine pranobex; 2) with clear description of disease diagnosis and determination of efficacy; 3) with follow-up information; 4) with a Jadad score of at least 2. Exclusion criteria: HIV related, cancer related, patients with alcoolihc or drug abuse.
- Comparator Control
- Placebo group, conventional treatment group, or a non-exposed control group. Inclusion and exclusion criteria could be found in above.
- Main Outcome
- The efficacy of inosine pranobex in the treatment of different human diseases or clinical applications. Measures of effect 1) During treatment or observation period after treatment, 2) Complete cure and/or remission of diseases, laboratory analysis
- Outcome Measure
- Additional Outcome
- Secondary outcomes included treatment methods and schedules, and adverse events. Measures of effect 1) During treatment or observation period after treatment
- Study Method
- Keyword
- Antiviral Agents; HIV Infections; Humans; Inosine; Inosine Pranobex; Neoplasms
- Contact
- Professor Mynbaev [email protected]
- Organisational Affiliation
- Laboratory of Human Physiology, Moscow Institute of Physics and Technology (State university) https://mipt.ru
- Funding Source
- NEWPORT PHARMACEUTICALS INTERNATIONAL
- Other Selection Criteria
- Final Publication
- Same Topic Review
- A systematic review [Russian] concerning application of Inosine pranobex in HPV-associated mucosal and skin lesions
- Published Protocol
- Review Type
- Language
- English
- Country
- China, Russian Federation, United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2016-01-19
- Anticipated Start Date
- 2015-11-09
- Anticipated Completion Date
- 2016-05-09
- Title Cn
- 异丙肌苷在非HIV和非癌症临床状况中的疗效
- Title En
- The efficacy of inosine pranobex in non-HIV and non-cancer clinical conditions
- Bilingual Status
- complete